SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
On June13, 2017, Sierra Oncology, Inc. (the Company) held its
2017 Annual Meeting of Stockholders and the following proposals
were adopted:
| 1. |
Election of two Class II directors, Nicole Onetto and Daniel Estes, each to serve a three-year term, which will expire at the 2020 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such directors earlier resignation or removal. The vote tally was as follows: |
|
Nominees |
Shares For |
SharesWithheld |
Broker Non-Votes |
|||
|
Nicole Onetto |
27,077,529 | 1,133,359 | 10,665,206 | |||
|
Daniel Estes |
27,688,459 | 522,429 | 10,665,206 |
| 2. |
Ratification of the appointment of Deloitte Touche LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017. The vote tally was as follows: |
|
Shares For |
SharesAgainst |
Shares Abstaining |
Broker Non-Votes |
|||
|
38,333,028 |
494,541 | 48,525 |
The stockholders did not approve the stockholder proposal
requesting that the Companys Board of Directors take the
necessary steps under applicable state law to declassify the
Board of Directors so that all directors are elected annually.
The vote tally was as follows:
|
Shares For |
SharesAgainst |
Shares Abstaining |
Broker Non-Votes |
|||
|
9,507,435 |
18,665,034 | 38,419 | 10,665,206 |
2
About SIERRA ONCOLOGY, INC. (NASDAQ:SRRA)
Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.
